The molecular biology of soft-tissue sarcomas and current trends in therapy

Sarcoma

Volumn 2012, Issue , 2012, Pages

  Quesada, Jorge ^a,b   Amato, Robert ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; AXITINIB; BRIVANIB; CANCER VACCINE; CEDIRANIB; CIXUTUMUMAB; CYTOKINE; EVEROLIMUS; FIGITUMUMAB; IMATINIB; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; MICRORNA; MONOCLONAL ANTIBODY; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PAZOPANIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RIDAFOROLIMUS; SOMATOMEDIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVANTINIB; UNINDEXED DRUG; VASCULOTROPIN; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANGIOGENESIS; ANGIOSARCOMA; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGISTRY; CANCER RESEARCH; CANCER STEM CELL; CELL CYCLE; CELL TRANSFORMATION; CHROMOSOME TRANSLOCATION; CYTOKINE PRODUCTION; DESMOPLASTIC SMALL ROUND CELL TUMOR; DRUG APPROVAL; DRUG EFFICACY; EMBRYONAL RHABDOMYOSARCOMA; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; EWING SARCOMA; FIBROSARCOMA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; GENE AMPLIFICATION; GENE DELETION; HARVEY SARCOMA ONCOVIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; KAPOSI SARCOMA; KARYOTYPE; KIRSTEN SARCOMA ONCOVIRUS; MALIGNANT TRANSFORMATION; MESENCHYMAL EPITHELIAL TRANSITION; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; MOLECULE; NONHUMAN; ONCOGENE K RAS; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROVIRUS; REVIEW; RHABDOMYOSARCOMA; ROUS SARCOMA ONCOVIRUS; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SOMATIC MUTATION; SYNOVIAL SARCOMA; TELOMERE; TREATMENT OUTCOME; TUMOR GROWTH; VIRUS CARCINOGENESIS; VIRUS ONCOGENE; VIRUS REPLICATION;

EID: 84862275926     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2012/849456     Document Type: Review

References (106)

1. Hanahan D., Weinberg R. A., Hallmarks of cancer: the next generation Cell 2011 144 5 646 674
2. Rous P., A sarcoma of the fowl transmissible by an agent separable from the tumor cells The Journal of Experimental Medicine 1911 13 397 411
3. Rubin H., The early history of tumor virology: Rous, RIF, and RAV Proceedings of the National Academy of Sciences of the United States of America 2011 108 35 14389 14396
4. Butel J. S., Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease Carcinogenesis 2000 21 3 405 426 (Pubitemid 30137926)
5. Huebner R. J., Todaro G. J., Oncogenes of rna tumor viruses as determinants of cancer Proceedings of the National Academy of Sciences of the United States of America 1969 64 3 1087 1094
6. Stehelin D., Varmus H. E., Bishop J. M., Vogt P. K., DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA Nature 1976 260 5547 170 173
7. Fearon E. R., Vogelstein B., A genetic model for colorectal tumorigenesis Cell 1990 61 5 759 767
8. Malumbres M., Barbacid M., RAS oncogenes: the first 30 years Nature Reviews Cancer 2003 3 6 459 465 (Pubitemid 37328850)
9. Goodsell D. S., The molecular perspective: the RAS oncogene Oncologist 1999 4 3 263 264 (Pubitemid 29297488)
10. Downward J., Targeting ras signalling pathways in cancer therapy Nature Reviews Cancer 2003 3 1 11 22 (Pubitemid 37328883)
11. Bickels J., Kollender Y., Merinsky O., Meller I., Coley's toxin: historical perspective Israel Medical Association Journal 2002 4 6 471 472 (Pubitemid 34624732)
12. Gresser I., Antitumor effects of interferon Advances in Cancer Research 1973 16 97 140
13. Strander H., Interferons and osteosarcoma Cytokine and Growth Factor Reviews 2007 18 5-6 373 380 (Pubitemid 47302835)
14. Platanias L. C., Mechanisms of type-I- and type-II-interferon-mediated signalling Nature Reviews Immunology 2005 5 5 375 386 (Pubitemid 40685987)
15. Panaretakis T., Hjortsberg L., Tamm K. P., Bjrklund A. C., Joseph B., Grander D., Interferon induces nucleus-independent apoptosis by activating extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase downstream of phosphatidylinositol 3-kinase and mammalian target of rapamycin Molecular Biology of the Cell 2008 19 1 41 50 (Pubitemid 351186131)
16. Hutt M. S. R., Historical introduction, burkitt's lymphoma, nasopharyngeal carcinoma and Kaposi's sarcoma Transactions of the Royal Society of Tropical Medicine and Hygiene 1981 75 6 761 765
17. Beral V., Peterman T. A., Berkelman R. L., Jaffe H. W., Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? The Lancet 1990 335 8682 123 128 (Pubitemid 20032724)
18. Moore P. S., Chang Y., Detection of herpesvirus-like dna sequences in Kaposi's sarcoma in patients with and those without HIV infection New England Journal of Medicine 1995 332 18 1181 1185
19. West J. T., Wood C., The role of Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 regulator of transcription activation (RTA) in control of gene expression Oncogene 2003 22 33 5150 5163 (Pubitemid 37059596)
20. Jenner R. G., Maillard K., Cattini N., Weiss R. A., Boshoff C., Wooster R., Kellam P., Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile Proceedings of the National Academy of Sciences of the United States of America 2003 100 18 10399 10404 (Pubitemid 37071890)
21. Wang H. W., Trotter M. W. B., Lagos D., Bourboulia D., Henderson S., Mkinen T., Elliman S., Flanagan A. M., Alitalo K., Boshoff C., Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma Nature Genetics 2004 36 7 687 693 (Pubitemid 38886628)
22. Krown S. E., Real F. X., Cunningham Rundles S., Preliminary observations on the effect of recombinant leukocyte a interferon in homosexual men with Kaposi's sarcoma New England Journal of Medicine 1983 308 18 1071 1076 (Pubitemid 13124896)
23. Rios A., Mansell P. W. A., Newell G. R., Treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma with lymphoblastoid interferon Journal of Clinical Oncology 1985 3 4 506 512 (Pubitemid 15116928)
24. Besmer P., Hardy W. D. Jr., Zuckerman E. E., The hardy-zuckerman 2-FeSV, a new feline retrovirus with oncogene homology to abelson-MuLV Nature 1983 303 5920 825 828 (Pubitemid 13054500)
25. Yarden Y., Kuang W. J., Yang-Feng T., Coussens L., Munemitsu S., Dull T. J., Chen E., Schlessinger J., Francke U., Ullrich A., Human proto-oncogene c-KIT: a new cell surface receptor tyrosine kinase for an unidentified ligand EMBO Journal 1987 6 11 3341 3351
26. Sircar K., Hewlett B. R., Huizinga J. D., Chorneyko K., Berezin I., Riddell R. H., Interstitial cells of cajal as precursors of gastrointestinal stromal tumors American Journal of Surgical Pathology 1999 23 4 377 389 (Pubitemid 29159998)
27. Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., Kawano K., Hanada M., Kurata A., Takeda M., Tunio G. M., Matsuzawa Y., Kanakura Y., Shinomura Y., Kitamura Y., Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors Science 1998 279 5350 577 580 (Pubitemid 28067289)
28. Heinrich M. C., Rubin B. P., Longley B. J., Fletcher J. A., Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations Human Pathology 2002 33 5 484 495 (Pubitemid 34747867)
29. Reichardt P., Optimal use of targeted agents for advanced gastrointestinal stromal tumours Oncology 2010 78 2 130 140
30. Heinrich M. C., Griffith D. J., Druker B. J., Wait C. L., Ott K. A., Zigler A. J., Inhibition of c-KIT receptor tyrosine kinase activity by STI 571 a selective tyrosine kinase inhibitor Blood 2000 96 3 925 932 (Pubitemid 30618049)
31. Tuveson D. A., Willis N. A., Jacks T., Griffin J. D., Singer S., Fletcher C. D. M., Fletcher J. A., Demetri G. D., STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications Oncogene 2001 20 36 5054 5058 (Pubitemid 32769795)
32. Joensuu H., Roberts P. J., Sarlomo-Rikala M., Andersson L. C., Tervahartiala P., Tuveson D., Silberman S. L., Capdeville R., Dimitrijevic S., Druker B., Demetri G. D., Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor New England Journal of Medicine 2001 344 14 1052 1056 (Pubitemid 32267975)
33. Demetri G. D., Von Mehren M., Blanke C. D., Van Den Abbeele A. D., Eisenberg B., Roberts P. J., Heinrich M. C., Tuveson D. A., Singer S., Janicek M., Fletcher J. A., Silverman S. G., Silberman S. L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B. J., Corless C., Fletcher C. D. M., Joensuu H., Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors New England Journal of Medicine 2002 347 7 472 480 (Pubitemid 34879334)
34. Singer S., Rubin B. P., Lux M. L., Chen C. J., Demetri G. D., Fletcher C. D. M., Fletcher J. A., Prognostic value of kit mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors Journal of Clinical Oncology 2002 20 18 3898 3905
35. Bauer S., Duensing A., Demetri G. D., Fletcher J. A., KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway Oncogene 2007 26 54 7560 7568 (Pubitemid 350207707)
36. lava E., Molecular pathology in sarcomas Clinical and Translational Oncology 2007 9 3 130 144
37. Bovée J. V. M. G., Hogendoorn P. C. W., Molecular pathology of sarcomas: concepts and clinical implications Virchows Archiv 2010 456 2 193 199
38. Oda Y., Tsuneyoshi M., Recent advances in the molecular pathology of soft tissue sarcoma: implications for diagnosis, patient prognosis, and molecular target therapy in the future Cancer Science 2009 100 2 200 208
39. Helman L. J., Meltzer P., Mechanisms of sarcoma development Nature Reviews Cancer 2003 3 9 685 694 (Pubitemid 37328823)
40. Mertens F., Panagopoulos I., Mandahl N., Genomic characteristics of soft tissue sarcomas Virchows Archiv 2010 456 2 129 139
41. Le Deley M. C., Delattre O., Schaefer K. L., Burchill S. A., Koehler G., Hogendoorn P. C. W., Lion T., Poremba C., Marandet J., Ballet S., Pierron G., Brownhill S. C., Nesslbck M., Ranft A., Dirksen U., Oberlin O., Lewis I. J., Craft A. W., Jrgens H., Kovar H., Impact of EWS-ETS fusion type on disease progression in ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial Journal of Clinical Oncology 2010 28 12 1982 1988
42. Guillou L., Benhattar J., Bonichon F., Gallagher G., Terrier P., Stauffer E., De Saint Aubain Somerhausen N., Michels J. J., Jundt G., Vince D. R., Taylor S., Genevay M., Collin F., Trassard M., Coindre J. M., Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis Journal of Clinical Oncology 2004 22 20 4040 4050 (Pubitemid 41185173)
43. Delattre O., Zucman J., Plougastel B., Desmaze C., Melot T., Peter M., Kovar H., Joubert I., De Jong P., Rouleau G., Aurias A., Thomas G., Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours Nature 1992 359 6391 162 165
44. Barr F. G., Translocations, cancer and the puzzle of specificity Nature Genetics 1998 19 2 121 124 (Pubitemid 28248791)
45. Knezevich S. R., McFadden D. E., Tao W., Lim J. F., Sorensen P. H. B., A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma Nature Genetics 1998 18 2 184 187 (Pubitemid 28082471)
46. Lannon C. L., Martin M. J., Tognon C. E., Jin W., Kim S. J., Sorensen P. H. B., A highly conserved NTRK3 c-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1: an essential interaction for transformation Journal of Biological Chemistry 2004 279 8 6225 6234 (Pubitemid 38248755)
47. Fujimura Y., Ohno T., Siddique H., Lee L., Rao V. N., Reddy E. S. P., The EWS-ATF-1 gene involved in malignant melanoma of soft parts with t(12;22) chromosome translocation, encodes a constitutive transcriptional activator Oncogene 1996 12 1 159 167 (Pubitemid 26041252)
48. Ladanyi M., Lui M. Y., Antonescu C. R., Krause-Boehm A., Meindl A., Argani P., Healey J. H., Ueda T., Yoshikawa H., Meloni-Ehrig A., Sorensen P. H. B., Mertens F., Mandahl N., Van Den Berghe H., Sciot R., Dal Cin P., Bridge J., The der(17)t(x;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25 Oncogene 2001 20 1 48 57 (Pubitemid 32142337)
49. Davis I. J., Kim J. J., Ozsolak F., Widlund H. R., Rozenblatt-Rosen O., Granter S. R., Du J., Fletcher J. A., Denny C. T., Lessnick S. L., Linehan W. M., Kung A. L., Fisher D. E., Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers Cancer Cell 2006 9 6 473 484 (Pubitemid 43832189)
50. Rikhof B., De Jong S., Suurmeijer A. J. H., Meijer C., Van Der Graaf W. T. A., The insulin-like growth factor system and sarcomas Journal of Pathology 2009 217 4 469 482
51. Zha J., Lackner M. R., Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy Clinical Cancer Research 2010 16 9 2512 2517
52. Kirsch D. G., Dinulescu D. M., Miller J. B., Grimm J., Santiago P. M., Young N. P., Nielsen G. P., Quade B. J., Chaber C. J., Schultz C. P., Takeuchi O., Bronson R. T., Crowley D., Korsmeyer S. J., Yoon S. S., Hornicek F. J., Weissleder R., Jacks T., A spatially and temporally restricted mouse model of soft tissue sarcoma Nature Medicine 2007 13 8 992 997 (Pubitemid 47222037)
53. Hernando E., Charytonowicz E., Dudas M. E., Menendez S., Matushansky I., Mills J., Socci N. D., Behrendt N., Ma L., Maki R. G., Pandolfi P. P., Cordon-Cardo C., The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas Nature Medicine 2007 13 6 748 753 (Pubitemid 46889749)
54. Sasaki K., Hitora T., Nakamura O., Kono R., Yamamoto T., The role of MAPK pathway in bone and soft tissue tumors Anticancer Research 2011 31 2 549 553
55. Peng C. L., Guo W., Ji T., Ren T., Yang Y., Li D. S., Qu H. Y., Li X., Tang S., Yan T. Q., Tang X. D., Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway Cancer Biology and Therapy 2009 8 18 1729 1736
56. Ding Y., Boguslawski E. A., Berghuis B. D., Young J. J., Zhang Z., Hardy K., Furge K., Kort E., Frankel A. E., Hay R. V., Resau J. H., Duesbery N. S., Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma Molecular Cancer Therapeutics 2008 7 3 648 658 (Pubitemid 351482147)
57. Vemulapalli S., Mita A., Alvarado Y., Sankhala K., Mita M., The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas Targeted Oncology 2011 6 1 29 39
58. Wan X., Helman L. J., The biology behind mtor inhibition in sarcoma Oncologist 2007 12 8 1007 1018 (Pubitemid 47359144)
59. Yang Q., Guan K. L., Expanding mTOR signaling Cell Research 2007 17 8 666 681 (Pubitemid 47255937)
60. Hogendoorn P. C. W., Collin F., Daugaard S., Dei Tos A. P., Fisher C., Schneider U., Sciot R., Changing concepts in the pathological basis of soft tissue and bone sarcoma treatment European Journal of Cancer 2004 40 11 1644 1654 (Pubitemid 38902898)
61. Chao C., Al-Saleem T., Brooks J. J., Rogatko A., Kraybill W. G., Eisenberg B., Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade Annals of Surgical Oncology 2001 8 3 260 267 (Pubitemid 32294808)
62. Olsen R. J., Tarantolo S. R., Hinrichs S. H., Molecular approaches to sarcoma therapy Sarcoma 2002 6 1 27 42 (Pubitemid 34620886)
63. Yoon S. S., Segal N. H., Park P. J., Detwiller K. Y., Fernando N. T., Ryeom S. W., Brennan M. F., Singer S., Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression Journal of Surgical Research 2006 135 2 282 290 (Pubitemid 44414877)
64. Costa A., Daidone M. G., Daprai L., Villa R., Cant S., Pilotti S., Mariani L., Gronchi A., Henson J. D., Reddel R. R., Zaffaroni N., Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression Cancer Research 2006 66 17 8918 8924 (Pubitemid 44449211)
65. Johnson J. E., Gettings E. J., Schwalm J., Pei J., Testa J. R., Litwin S., Von Mehren M., Broccoli D., Whole-genome profiling in liposarcomas reveals genetic alterations common to specific telomere maintenance mechanisms Cancer Research 2007 67 19 9221 9228 (Pubitemid 47535909)
66. Takebe N., Harris P. J., Warren R. Q., Ivy S. P., Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways Nature Reviews Clinical Oncology 2011 8 2 97 106
67. Jordan C. T., Cancer stem cell biology: from leukemia to solid tumors Current Opinion in Cell Biology 2004 16 6 708 712 (Pubitemid 39463123)
68. Suv M. L., Riggi N., Stehle J. C., Baumer K., Tercier S., Joseph J. M., Suv D., Clément V., Provero P., Cironi L., Osterheld M. C., Guillou L., Stamenkovic I., Identification of cancer stem cells in ewing's sarcoma Cancer Research 2009 69 5 1776 1781
69. Riggi N., Cironi L., Provero P., Suv M. L., Stehle J. C., Baumer K., Guillou L., Stamenkovic I., Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma Cancer Research 2006 66 14 7016 7023 (Pubitemid 44197677)
70. Chaffer C. L., Thompson E. W., Williams E. D., Mesenchymal to epithelial transition in development and disease Cells Tissues Organs 2007 185 13 7 19 (Pubitemid 46956838)
71. Laskin W. B., Miettinen M., Epithelial-type and neural-type cadherin expression in malignant noncarcinomatous neoplasms with epithelioid features that involve the soft tissues Archives of Pathology and Laboratory Medicine 2002 126 4 425 431 (Pubitemid 34286806)
72. Saito T., Nagai M., Ladanyi M., SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma Cancer Research 2006 66 14 6919 6927 (Pubitemid 44197666)
73. Fitzgerald M. P., Gourronc F., Teoh M. L. T., Provenzano M. J., Case A. J., Martin J. A., Domann F. E., Human chondrosarcoma cells acquire an epithelial-like gene expression pattern via an epigenetic switch: evidence for mesenchymal-epithelial transition during sarcomagenesis Sarcoma 2011 2011 11
74. Gammell P., Micrornas: recently discovered key regulators of proliferation and apoptosis in animal cells: identification of mirnas regulating growth and survival Cytotechnology 2007 53 13 55 63 (Pubitemid 46944869)
75. Subramanian S., Lui W. O., Lee C. H., Espinosa I., Nielsen T. O., Heinrich M. C., Corless C. L., Fire A. Z., Van De Rijn M., Microrna expression signature of human sarcomas Oncogene 2008 27 14 2015 2026 (Pubitemid 351442735)
76. Hisaoka M., Matsuyama A., Nagao Y., Luan L., Kuroda T., Akiyama H., Kondo S., Hashimoto H., Identification of altered microrna expression patterns in synovial sarcoma Genes Chromosomes and Cancer 2011 50 3 137 145
77. Motoi T., Kumagai A., Yoshida A., MicroRNA-200a Expression in Synovial Sarcoma Is Related to Epithelial Differentiation. Abstract 65, http://www.abstracts2view.com/uscap11/
78. Riggi N., Suv M. L., De Vito C., Provero P., Stehle J. C., Baumer K., Cironi L., Janiszewska M., Petricevic T., Suv D., Tercier S., Joseph J. M., Guillou L., Stamenkovic I., EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward ewing sarcoma cancer stem cells Genes and Development 2010 24 9 916 932
79. Weroha S. J., Haluska P., GF-1 receptor inhibitors in clinical trialsearly lessons Journal of Mammary Gland Biology and Neoplasia 2008 13 4 471 483
80. Olmos D., Postel-Vinay S., Molife L. R., Okuno S. H., Schuetze S. M., Paccagnella M. L., Batzel G. N., Yin D., Pritchard-Jones K., Judson I., Worden F. P., Gualberto A., Scurr M., de Bono J. S., Haluska P., Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R -1R antibody figitumumab (CP-751,871) in patients with sarcoma and ewing's sarcoma: a phase 1 expansion cohort study The Lancet Oncology 2010 11 2 129 135
81. Houghton P. J., Morton C. L., Gorlick R., Kolb E. A., Keir S. T., Reynolds C. P., Kang M. H., Maris J. M., Wu J., Smith M. A., Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program Pediatric Blood and Cancer 2010 54 7 921 926
82. Tolcher A. W., Sarantopoulos J., Patnaik A., Papadopoulos K., Lin C. C., Rodon J., Murphy B., Roth B., McCaffery I., Gorski K. S., Kaiser B., Zhu M., Deng H., Friberg G., Puzanov I., Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1 Journal of Clinical Oncology 2009 27 34 5800 5807
83. Pappo A. S., Patel S., Crowley J., Activity of R1507, a monoclonal antibody to the insulinlike growth factor-1 receptor (IGF1R), in patients with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): results of a phase II SARC study Journal of Clinical Oncology 2010 28, supplement 15, abstract 10000
84. Martins A. S., Mackintosh C., Herrero Martn D., Campos M., Hernndez T., Ordez J. L., De Alava E., Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in ewing tumor Clinical Cancer Research 2006 12 11 3532 3540
85. Godwin A. K., Rink L., Chi T., Insulin-like growth factor 1 receptor (IGF-1R): a potential therapeutic target for gastrointestinal stromal tumors (GIST) Journal of Clinical Oncology 2008 26, supplement, abstract 10507
86. George S., Merriam P., Maki R. G., Van Den Abbeele A. D., Yap J. T., Akhurst T., Harmon D. C., Bhuchar G., O'Mara M. M., D'Adamo D. R., Morgan J., Schwartz G. K., Wagner A. J., Butrynski J. E., Demetri G. D., Keohan M. L., Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas Journal of Clinical Oncology 2009 27 19 3154 3160
87. Homet Moreno B., Garralda Cabanas E., Hitt R., Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas Clinical and Translational Oncology 2010 12 7 468 472
88. Maki R. G., D'Adamo D. R., Keohan M. L., Saulle M., Schuetze S. M., Undevia S. D., Livingston M. B., Cooney M. M., Hensley M. L., Mita M. M., Takimoto C. H., Kraft A. S., Elias A. D., Brockstein B., Blachre N. E., Edgar M. A., Schwartz L. H., Qin L. X., Antonescu C. R., Schwartz G. K., Phase II study of sorafenib in patients with metastatic or recurrent sarcomas Journal of Clinical Oncology 2009 27 19 3133 3140
89. Sleijfer S., Ray-Coquard I., Papai Z., Le Cesne A., Scurr M., Schffski P., Collin F., Pandite L., Marreaud S., De Brauwer A., Van Glabbeke M., Verweij J., Blay J. Y., Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the european organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043) Journal of Clinical Oncology 2009 27 19 3126 3132
90. Van Der Graaf W. T., Blay J., Chawla S. P., PALETTE: a randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy Journal of Clinical Oncology 2011 29, supplement, abstract LBA10002
91. Schwartz G. S., Maki R. G., Ratain M. J., Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): biomarker and subset results of a phase II randomized discontinuation trial Journal of Clinical Oncology 2011 29, supplement, abstract 10000
92. Kummar S., Strassberger A., Monks A., An evaluation of cediranib as a new agent for alveolar soft part sarcoma Journal of Clinical Oncology 2011 29, supplement, abstract 10001
93. Goldberg J., Demetri G. D., Choy E., Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors Journal of Clinical Oncology 2009 27, supplement 15, abstract 10502
94. Riedel R. F., Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches Cancer 2012 118 6 1474 1485
95. Amato R. J., Jac J., Targeted anti-cancer therapies for renal cancer Drugs 2006 66 17 2161 2171 (Pubitemid 44878527)
96. Rivera V. M., Squillace R. M., Miller D., Berk L., Wardwell S. D., Ning Y., Pollock R., Narasimhan N. I., Iuliucci J. D., Wang F., Clackson T., Ridaforolimus (AP23573; MK-8669), a potent mtor inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens Molecular Cancer Therapeutics 2011 10 6 1059 1071
97. Agulnik M., New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma Cancer 2012 118 6 1486 1497
98. Chawla S. P., Blay J., Ray-Coquard I. L., Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy Journal of Clinical Oncology 2011 29, supplement, abstract 10005
99. Vemulapalli S., Mita A., Alvarado Y., Sankhala K., Mita M., The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas Targeted Oncology 2011 6 1 29 39
100. Vijayalaxmi C. R., Thomas R., Reiter R., Herman T. S., Melatonin: from basic research to cancer treatment clinics Journal of Clinical Oncology 2002 20 10 2575 2601 (Pubitemid 34525746)
101. Casado-Zapico S., Rodriguez-Blanco J., Garca-Santos G., Martn V., Snchez-Snchez A. M., Antoln I., Rodriguez C., Synergistic antitumor effect of melatonin with several chemotherapeutic drugs on human ewing sarcoma cancer cells: potentiation of the extrinsic apoptotic pathway Journal of Pineal Research 2010 48 1 72 80
102. Sahra I. B., Marchand-Brustel Y. L., Tanti J. F., Bost F., Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Molecular Cancer Therapeutics 2010 9 5 1092 1099
103. Richter S., Pink D., Hohenberger P., Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST Journal of Clinical Oncology 2010 28, 15s, supplement, abstract 10038
104. Jaffe C. C., Response assessment in clinical trials: implications for sarcoma clinical trial design Oncologist 2008 13 supplement 2 14 18
105. Gayed I., Vu T., Iyer R., Johnson M., Macapinlac H., Swanston N., Podoloff D., The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors Journal of Nuclear Medicine 2004 45 1 17 21 (Pubitemid 47611603)
106. Wahl R. L., Jacene H., Kasamon Y., Lodge M. A., From recist to percist: evolving considerations for pet response criteria in solid tumors Journal of Nuclear Medicine 2009 50 supplement 5 122 150